Publication:
Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment

38

Issued Date

2020-03-01

Resource Type

Article

ISSN

15389375
15258610

DOI

10.1016/j.jamda.2019.12.012

Other identifier(s)

2-s2.0-85078822376

Rights

Mahidol University

Rights Holder(s)

SCOPUS

Bibliographic Citation

Journal of the American Medical Directors Association. Vol.21, No.3 (2020), 300-307.e2

Suggested Citation

Liang Kung Chen, Jean Woo, Prasert Assantachai, Tung Wai Auyeung, Ming Yueh Chou, Katsuya Iijima, Hak Chul Jang, Lin Kang, Miji Kim, Sunyoung Kim, Taro Kojima, Masafumi Kuzuya, Jenny S.W. Lee, Sang Yoon Lee, Wei Ju Lee, Yunhwan Lee, Chih Kuang Liang, Jae Young Lim, Wee Shiong Lim, Li Ning Peng, Ken Sugimoto, Tomoki Tanaka, Chang Won Won, Minoru Yamada, Teimei Zhang, Masahiro Akishita, Hidenori Arai Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. Journal of the American Medical Directors Association. Vol.21, No.3 (2020), 300-307.e2. doi:10.1016/j.jamda.2019.12.012 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/53748

Research Projects

Organizational Units

Authors

Journal Issue

Thesis

Title

Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment

Author(s)

Liang Kung Chen
 Jean Woo
 Prasert Assantachai
 Tung Wai Auyeung
 Ming Yueh Chou
 Katsuya Iijima
 Hak Chul Jang
 Lin Kang
 Miji Kim
 Sunyoung Kim
 Taro Kojima
 Masafumi Kuzuya
 Jenny S.W. Lee
 Sang Yoon Lee
 Wei Ju Lee
 Yunhwan Lee
 Chih Kuang Liang
 Jae Young Lim
 Wee Shiong Lim
 Li Ning Peng
 Ken Sugimoto
 Tomoki Tanaka
 Chang Won Won
 Minoru Yamada
 Teimei Zhang
 Masahiro Akishita
 Hidenori Arai

Other Contributor(s)

Seoul National University Bundang Hospital
 Seoul Metropolitan Government - Seoul National University Borame Medical Center
 National Yang-Ming University Taiwan
 Ajou University, School of Medicine
 National Center for Geriatrics and Gerontology - National Institute for Longevity Sciences
 University of Tokyo
 Veterans General Hospital-Kaohsiung Taiwan
 Nagoya University School of Medicine
 University of Tsukuba
 Osaka University Faculty of Medicine
 Veterans General Hospital-Taipei
 Faculty of Medicine, Siriraj Hospital, Mahidol University
 Peking Union Medical College Hospital
 Chinese University of Hong Kong
 Tan Tock Seng Hospital
 Kyung Hee University
 Beijing Hospital

Abstract

© 2019 AMDA – The Society for Post-Acute and Long-Term Care Medicine Clinical and research interest in sarcopenia has burgeoned internationally, Asia included. The Asian Working Group for Sarcopenia (AWGS) 2014 consensus defined sarcopenia as “age-related loss of muscle mass, plus low muscle strength, and/or low physical performance” and specified cutoffs for each diagnostic component; research in Asia consequently flourished, prompting this update. AWGS 2019 retains the previous definition of sarcopenia but revises the diagnostic algorithm, protocols, and some criteria: low muscle strength is defined as handgrip strength <28 kg for men and <18 kg for women; criteria for low physical performance are 6-m walk <1.0 m/s, Short Physical Performance Battery score ≤9, or 5-time chair stand test ≥12 seconds. AWGS 2019 retains the original cutoffs for height-adjusted muscle mass: dual-energy X-ray absorptiometry, <7.0 kg/m2 in men and <5.4 kg/m2 in women; and bioimpedance, <7.0 kg/m2 in men and <5.7 kg/m2 in women. In addition, the AWGS 2019 update proposes separate algorithms for community vs hospital settings, which both begin by screening either calf circumference (<34 cm in men, <33 cm in women), SARC-F (≥4), or SARC-CalF (≥11), to facilitate earlier identification of people at risk for sarcopenia. Although skeletal muscle strength and mass are both still considered fundamental to a definitive clinical diagnosis, AWGS 2019 also introduces “possible sarcopenia,” defined by either low muscle strength or low physical performance only, specifically for use in primary health care or community-based health promotion, to enable earlier lifestyle interventions. Although defining sarcopenia by body mass index–adjusted muscle mass instead of height-adjusted muscle mass may predict adverse outcomes better, more evidence is needed before changing current recommendations. Lifestyle interventions, especially exercise and nutritional supplementation, prevail as mainstays of treatment. Further research is needed to investigate potential long-term benefits of lifestyle interventions, nutritional supplements, or pharmacotherapy for sarcopenia in Asians.

Keyword(s)

Medicine
 Nursing

Availability

URI

https://repository.li.mahidol.ac.th/handle/123456789/53748

Collections

Scopus 2020